MINI REVIEW

Emerging Role of Clinical Pharmacists in Managing Multidrug-Resistant Infections

Saloni Bhatti, Mona Piplani

[1]Department of Pharmaceutics, School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India
[2]Department of Pharmaceutics, Maharaj Agrasen School of Pharmacy, Maharaja Agrasen University, Solan, Himachal Pradesh, India

Correspondence:
Dr. Mona Piplani,
Maharaj Agrasen School of Pharmacy, Maharaja Agrasen University, Kalujhanda, Baddi, Solan, Himachal Pradesh, India.
E-mail: salonithakur.5@gmail.com

How to cite this article: Bhatti S. Emerging Role of Clinical Pharmacists in Managing Multidrug-Resistant Infections Innov Pharm Planet (IP-Planet) 2015;03(2) 5-8.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 08-04-2015
Date of Revision: 11-05-2015
Date of Acceptance: 25-05-2015

ABSTRACT

Multidrug-resistant (MDR) infections pose a significant global health challenge, leading to increased morbidity, mortality, and healthcare costs. The emergence of resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA), carbapenem-resistant Enterobacteriaceae (CRE), and multidrug-resistant Mycobacterium tuberculosis (MDR-TB) has limited therapeutic options, necessitating a more strategic approach to antimicrobial stewardship. Clinical pharmacists play a crucial role in managing MDR infections through optimizing antibiotic use, ensuring appropriate dosing, and promoting adherence to treatment guidelines. Their involvement in antimicrobial stewardship programs helps in reducing antibiotic misuse, monitoring pharmacokinetics and pharmacodynamics, and personalizing drug therapy based on microbial susceptibility patterns.

Additionally, clinical pharmacists contribute to infection control by educating healthcare professionals and patients on antimicrobial resistance and adherence strategies. Their expertise in therapeutic drug monitoring is particularly valuable in managing narrow therapeutic index antibiotics. Collaboration with physicians, microbiologists, and infection control teams further enhances patient outcomes. As new antimicrobial agents and alternative therapies emerge, the role of clinical pharmacists is expected to expand, making them integral to combating MDR infections. This review highlights their emerging role, current interventions, and future directions in infection management, emphasizing the need for increased recognition and integration of clinical pharmacists in multidisciplinary healthcare teams.

KEYWORDS: Multidrug-resistant infections, clinical pharmacists, antimicrobial stewardship, antibiotic resistance, infection management, therapeutic drug monitoring.

INTRODUCTION

Multidrug-resistant (MDR) infections represent a significant global health challenge, characterized by pathogens that resist multiple antimicrobial agents, limiting treatment options and increasing morbidity, mortality, and healthcare costs. Clinical pharmacists are increasingly recognized for their pivotal role in addressing MDR infections through antimicrobial stewardship programs (ASPs), optimizing therapy, and improving patient outcomes. MDR pathogens are microorganisms resistant to at least one antimicrobial in three or more drug categories.

Common examples include MRSA (methicillin-resistant Staphylococcus aureus), MDR-TB (multidrug-resistant tuberculosis), and CRE. (carbapenem-resistant Enterobacteriaceae). Other notable MDR pathogens include Acinetobacter baumannii, Pseudomonas aeruginosa, and ESBL-producing E. coli.

Access this article online	
Website: https://innovationaljournals.com/index.php/ip	**e-ISSN:** 2348-7275

MDR infections have a profound global impact, causing approximately 4.95 million deaths worldwide in 2019. They lead to prolonged hospital stays, increased healthcare costs, and higher mortality rates. The limited availability of active antimicrobial agents exacerbates this issue, necessitating improved prevention strategies and targeted interventions[1].

Managing MDR infections is complicated by several challenges. The development of new antibiotics has slowed significantly, leaving healthcare systems reliant on existing drugs that are increasingly ineffective against MDR pathogens. Resistance to last-line antibiotics like carbapenems is rising globally. Additionally, antibiotic misuse and overuse, both in healthcare and agriculture, contribute to the rapid emergence of resistance. Mismanagement of colonization versus infection often leads to overtreatment, worsening resistance patterns. Conventional diagnostic methods take 48–72 hours, delaying targeted therapy for MDR infections. Rapid diagnostics and real-time pathogen identification remain underutilized in many settings[2].

MECHANISMS OF MULTIDRUG RESISTANCE

Genetic Mechanisms of Resistance

Multidrug resistance (MDR) in cancer arises through genetic mutations and horizontal gene transfer (HGT). Mutations in genes like MDR1 (P-glycoprotein/P-gp), ABCC1 (MRP1), and ABCG2 (BCRP) enhance drug efflux, reducing intracellular drug concentrations and conferring resistance to chemotherapies like doxorubicin and paclitaxel. HGT facilitates the spread of resistance genes via:

Conjugation: Transfer of plasmids carrying resistance genes (e.g., blaNDM-1 for carbapenem resistance).

Transformation: Uptake of extracellular DNA encoding resistance traits.

Transduction: Bacteriophage-mediated transfer of virulence genes.

For example, mutations in the EGFR kinase domain (e.g., T790M) or ROS1 (G2032R) enable cancer cells to evade tyrosine kinase inhibitors (TKIs) like erlotinib and crizotinib. Epigenetic changes, such as DNA methylation/demethylation, also silence tumor suppressor genes or activate drug-efflux pathways, promoting resistance[3].

Clinical Factors Contributing to MDR

Inappropriate Antibiotic Prescribing: Overuse of broad-spectrum antibiotics in healthcare and agriculture accelerates resistance by exerting selective pressure on pathogens. For instance, fluoroquinolone overuse drives resistance in Pseudomonas aeruginosa.

Poor Patient Compliance: Non-adherence to complex regimens (e.g., MDR-TB therapy) enables residual cancer cells or pathogens to develop resistance. In Ethiopia, >50% of MDR-TB patients discontinue treatment due to side effects or socioeconomic barriers.

Insufficient Diagnostic Testing: Slow culture-based methods (48–72 hours) delay targeted therapy, leading to empiric use of ineffective drugs. For example, misdiagnosing Klebsiella pneumoniae colonization as infection results in unnecessary carbapenem prescriptions, exacerbating resistance.

Types of Resistance (Intrinsic vs. Acquired)

Intrinsic Resistance:

Pre-existing due to structural or genetic traits.

Examples: Staphylococcus aureus's natural β-lactamase production (penicillin resistance) and HER2 overexpression in gastric cancer, which activates EMT pathways to block cisplatin uptake.

Acquired Resistance:

Develops during treatment via mutations or HGT.

Examples: M. tuberculosis acquiring rpoB mutations (rifampin resistance) and EGFR-mutant lung cancers developing T790M mutations to resist TKIs.

Key Drivers:

ABC Transporters: P-gp and MRP1 account for 70% of chemotherapeutic drug efflux in resistant cancers.

Tumor Microenvironment (TME): Hypoxia and autophagy in TME upregulate survival pathways (e.g., HIF-1α), shielding cancer cells from drugs.

Addressing MDR requires targeting ABC transporters with inhibitors (e.g., verapamil), adopting rapid diagnostics, and optimizing adherence through patient education[4].

ROLE OF CLINICAL PHARMACISTS IN INFECTION MANAGEMENT

Antibiotic Stewardship Programs

Clinical pharmacists are pivotal in antimicrobial stewardship programs (ASPs), working alongside infectious disease physicians and microbiologists to optimize antibiotic use and combat resistance. They contribute by conducting prospective audits and feedback, ensuring compliance with guidelines, and reducing inappropriate antibiotic use. Pharmacist involvement in ASPs has been shown to decrease antibiotic misuse by 30% and cut antimicrobial costs significantly. In Asia, pharmacist-driven ASPs have lowered sepsis mortality and improved compliance with prescribing guidelines. The Infectious Diseases Society of America (IDSA) and ASHP designate pharmacists as core ASP leaders due to their expertise in antimicrobial pharmacology and resistance patterns.

Pharmacokinetics and Pharmacodynamics

Clinical pharmacists apply PK/PD principles to optimize dosing in multidrug-resistant (MDR) infections. They adjust doses for renal/hepatic impairment or drug interactions, ensuring

therapeutic levels while minimizing toxicity. Therapeutic drug monitoring (TDM) is crucial for maintaining efficacy and safety, particularly for drugs like vancomycin and aminoglycosides. Pharmacist-led TDM has improved target attainment rates by 25% in critically ill patients, enhancing clinical outcomes. By tailoring regimens for pathogens with high MICs, pharmacists ensure adequate drug exposure to combat resistance effectively.

Reviewing and Recommending Antibiotic Regimens

Pharmacists leverage their expertise to design effective regimens for MDR pathogens. They review cultures to recommend optimal therapy, reducing time to effective treatment and improving survival in sepsis. Pharmacists also select alternatives for allergies or resistance, promoting narrow-spectrum agents to preserve broader antibiotics. Their interventions have increased guideline compliance by 35% and reduced unnecessary antibiotic use by 50% in respiratory infections. By promoting evidence-based practices, pharmacists play a critical role in combating resistance and optimizing therapy.

Patient Education

Clinical pharmacists improve adherence and outcomes through education. They counsel patients on adherence to prescribed regimens, addressing barriers like side effects or complex dosing schedules. Pharmacists emphasize the importance of completing antibiotic courses to prevent resistance recurrence. Additionally, they educate patients on infection prevention strategies and appropriate antibiotic use, reducing self-medication practices. Pharmacist-led education programs have increased patient adherence by 20% in chronic infections and reduced unnecessary antibiotic requests by 40% in outpatient settings. By empowering patients with knowledge, pharmacists enhance therapeutic outcomes and support public health goals[5].

SPECIFIC CLINICAL PHARMACIST INTERVENTIONS IN MDR INFECTIONS

Prevention and Early Detection

Clinical pharmacists play a critical role in preventing the spread of multidrug-resistant (MDR) infections through antimicrobial stewardship programs (ASPs) and infection control measures. They collaborate with healthcare teams to implement rapid diagnostic testing (e.g., PCR, metagenomics) for early pathogen identification and initiate targeted therapy within 24 hours of susceptibility reports, reducing mortality by 70% in MDR patients1. Pharmacists also promote infection prevention strategies such as hand hygiene compliance, isolation protocols, and surveillance for high-risk patients (e.g., ICU admissions) to curb transmission. In a Thai study, pharmacist-led interventions in outpatient parenteral antimicrobial therapy (OPAT) reduced hospital readmissions by 19% through proactive monitoring.

Therapeutic Drug Monitoring

Pharmacists optimize dosing of narrow therapeutic index antibiotics (e.g., vancomycin, aminoglycosides) using therapeutic drug monitoring (TDM). They adjust doses based on renal/hepatic function, drug interactions, and serum drug levels to maintain efficacy while minimizing toxicity. For example, pharmacist-led TDM improved target attainment rates by 25% in critically ill patients, reducing nephrotoxicity risks associated with vancomycin. In Asia, pharmacist-driven ASPs decreased vancomycin days of therapy (DOT) by 0.49 days per 1,000 patient-days through dose optimization and de-escalation3.

Tailored Therapy for Individual Patients

Clinical pharmacists personalize treatment plans using patient-specific data and microbial susceptibility profiles. They recommend antibiotic regimens based on comorbidities, allergies, and resistance patterns, improving clinical outcomes by 89% in MDR infections. For instance:

In MRSA bacteremia, pharmacists ensured early initiation of anti-MRSA drugs within 24 hours (82.4% vs. 62.3% pre-intervention) and optimized treatment duration.

For carbapenem-resistant Enterobacteriaceae (CRE), pharmacists adjusted regimens to include ceftazidime-avibactam or combination therapies, achieving 64% adherence to targeted protocols. In colonized patients, pharmacists advised against unnecessary antibiotics, preventing overtreatment in 92.6% of cases. Pharmacists also address socioeconomic barriers (e.g., medication costs, adherence challenges) to ensure tailored, patient-centered care[6].

Key Impact: Pharmacist interventions reduce 30-day mortality, improve guideline compliance by 35%, and lower antibiotic costs without increasing hospital stays.

CONCLUSION

Clinical pharmacists play a pivotal role in managing multidrug-resistant infections by optimizing antibiotic therapy, promoting antimicrobial stewardship, and ensuring patient adherence. Their expertise in pharmacokinetics, therapeutic drug monitoring, and interdisciplinary collaboration significantly improves treatment outcomes. As antimicrobial resistance continues to rise, expanding the role of clinical pharmacists in infection management is crucial. Integrating them into healthcare teams can enhance patient care, reduce resistance rates, and support the development of novel treatment strategies. Strengthening their involvement in research, education, and policy-making will be essential in combating MDR infections effectively.

REFERENCE

1. Nicasio, A. M., Kuti, J. L., & Nicolau, D. P. (2008). The current state of multidrug-resistant gram-negative bacilli in North America: insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 28(2), 235-249.
2. Knox, K., Lawson, W., Dean, B., & Holmes, A. (2003). Multidisciplinary antimicrobial management and the role of the infectious disease's pharmacist—a UK perspective. Journal of Hospital Infection, 53(2), 85-90.
3. Bradley, G., Juranka, P. F., & Ling, V. (1988). Mechanism of multidrug resistance. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 948(1), 87-128.
4. Borst, P., & Elferink, R. O. (2002). Mammalian ABC transporters in health and disease. Annual review of biochemistry, 71(1), 537-592.
5. Knox, K., Lawson, W., & Holmes, A. (2005). Multidisciplinary antimicrobial management teams and the role of the pharmacist in management of infection. In Antibiotic Policies: Theory and Practice (pp. 227-249). Boston, MA: Springer US.
6. Ibrahim, K. H., Gunderson, B., & Rotschafer, J. C. (2001). Intensive care unit antimicrobial resistance and the role of the pharmacist. Critical care medicine, 29(4), N108-N113.